The information provided in this site is intended only for media, financial analysts and healthcare professionals.
Venous thrombo-embolism (thrombophlebitis and pulmonary embolism) and arterial thrombotic diseases represent a serious public health issue1,2. Epidemiologic models have suggested that in western countries deep vein thrombosis and their pulmonary embolism complications claim more lives annually than breast cancer and car accidents together, despite the existence of effective anti-thrombotic therapies such as Low Molecular Weigh Heparins (LMWH).
Venous thrombo-embolism (VTE) and arterial thrombosis can affect frail populations already suffering from medical conditions, affected by surgical operations, or suffering from acute coronary syndromes (diverse forms of heart attacks)2,3. Due to the extreme seriousness of some of these conditions, it is critical for a given [LMW] Heparin to display a predictable antithrombotic profile without compromising the patient’s safety.
1. Gerotziafas GT, Samama MM. Prophylaxis of venous thromboembolism in medical patients. Curr Opin Pulm Med. 2004;10(5):356-65.
2. Cohen AT on behalf of the VTE Impact Assessment Group in Europe (VITAE). Venous Thromboembolism in Europe: The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756-76.
3. Samama et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341:793-800.
© Sanofi 2004-2014 - All rights reserved - Update: October 19, 2011